Advertisement

Clinical characteristics of symptomatic narcolepsy or hypersomnia: an analysis of 182 consecutive cases with neurological disorders associated with hypersomnolence

  • H. Ono
  • T. Kanbayashi
  • A. Imanishi
  • T. Ayabe
  • Y. Sagawa
  • K. Tsutsui
  • Y. Ohmori
  • M. Takeshima
  • S. Nishino
  • T. Shimizu
Original Article
  • 25 Downloads

Abstract

Purpose

Symptomatic narcolepsy is characterized as low orexin (hypocretin) levels (≤ 110 pg/ml) due to neurological diseases. However, we have experienced the cases that show symptoms similar to narcolepsy, complaining of pathological sleepiness even in cases with intermediate orexin levels (110–200 pg/ml). Therefore, we reevaluated the previously reported cases to make the concept of disease to the group in which the orexin concentration is intermediate.

Methods

Although orexin-deficient symptomatic narcolepsy has been reported worldwide, facilities that are capable of measuring orexin are still limited. Currently, our laboratory handles with almost all the CSF samples from Asian countries for determining orexin levels. We measured over 2500 cases including 182 cases suspected of symptomatic narcolepsy/hypersomnolence. Therefore, we subdivided these cases into three groups according to CSF orexin levels, low orexin group (≤ 110 pg/ml), intermediate orexin group (110–200 pg/ml), and normal orexin group (> 200 pg/ml). We defined “symptomatic hypersomnia” for hypersomnolence cases with intermediate CSF orexin levels. MSLT was recommended but not necessary. Short sleep latency (< 8 min) without SOREMPs should be observed on MSLT when performed. We compared symptoms (excessive daytime sleepiness and cataplexy) and objective measures (mean sleep latency and number of SOREMPs in MSLT) among the three groups, attempting to characterize the “symptomatic hypersomnia” group.

Result

Among the 182 cases with clinical hypersomnolence, there were 32 cases of symptomatic narcolepsy (16%) and 14 cases of symptomatic hypersomnia (8%). Causative diseases of symptomatic narcolepsy cases consist of immune-mediated demyelinating disorders (34%) and neurodegenerations (19%), whereas those of symptomatic hypersomnia are immune-mediated demyelinating disorders (43%) and encephalopathies (14%). Significant differences were not found between orexin levels and the existence of cataplexy, SOREMPs, and short sleep latency among three hypersomnolence groups. From these results, we found that it is difficult to estimate orexin concentration from subjective symptoms and PSG/MSLT findings.

Conclusion

We identified that 32 symptomatic narcolepsy and 14 cases of symptomatic hypersomnolence with intermediate CSF orexin levels. We proposed these latter cases as a novel category of “symptomatic hypersomnia”. Currently, symptomatic hypersomnia cases with intermediate orexin levels or short sleep latency (< 8 min) without SOREMPs were not classified as a specific entity. However, symptomatic hypersomnia had similar severity of hypersomnolence symptoms to symptomatic narcolepsy. Therefore, these cases including equivalent pathophysiology are enough to make a comparable category as “symptomatic hypersomnia”. Since it is difficult to estimate the orexin concentration from subjective symptoms and physiological findings (PSG/MSLT), further studies for the characterization of “symptomatic hypersomnia” and understanding its pathophysiology are necessary.

Keywords

Hypersomnolence Narcolepsy Hypersomnia Orexin Sleep disorder 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical approval

This study was approved by ethical committees at Akita University and it is conformed to the provisions of the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9:269–310.CrossRefGoogle Scholar
  2. 2.
    Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8:373–99.CrossRefGoogle Scholar
  3. 3.
    Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553–62.CrossRefGoogle Scholar
  4. 4.
    Nishino S. The hypocretin/orexin system in health and disease. Bio Psychiatry. 2003;54:87–95.CrossRefGoogle Scholar
  5. 5.
    Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78.CrossRefGoogle Scholar
  6. 6.
    Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell. 1998;92:573–85.CrossRefGoogle Scholar
  7. 7.
    De Lecca L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322–7.CrossRefGoogle Scholar
  8. 8.
    Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996–10015.CrossRefGoogle Scholar
  9. 9.
    Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365–76.CrossRefGoogle Scholar
  10. 10.
    Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437–51.CrossRefGoogle Scholar
  11. 11.
    Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40.CrossRefGoogle Scholar
  12. 12.
    Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991–7.CrossRefGoogle Scholar
  13. 13.
    Nishino S, Ripley B, Overeen S, et al. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50:381–8.CrossRefGoogle Scholar
  14. 14.
    American Academy of Sleep Medicine. The international classification of sleep disorders diagnostic and coding manual, 2nd edn. Winchester: American Academy of Sleep Medicine; 2005.Google Scholar
  15. 15.
    American Academy of Sleep Medicine. The international classification of sleep disorders diagnostic and coding manual, 3rd edn. Winchester: American Academy of Sleep Medicine; 2014.Google Scholar
  16. 16.
    Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. pp. 24–57.CrossRefGoogle Scholar
  17. 17.
    Ritchie C, Okuro M, Kanbayashi T, Nishino S. Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. Curr Neurol Neurosci. 2010;10:180–9.CrossRefGoogle Scholar
  18. 18.
    Scammell TE, Nishino S, Mignot E, et al. Narcolepsy and low CFS orexin (hypocretin) concentration after diencephalic stroke. Neurology. 2001;56:1751–3.CrossRefGoogle Scholar
  19. 19.
    Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol. 2009;66(12):1563–6.CrossRefGoogle Scholar
  20. 20.
    Ripley B, Fujiki N, Okura M, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;57:2253–8.CrossRefGoogle Scholar
  21. 21.
    Tachibana N, Howar RS, Hirsch NP, et al. Sleep problems in multiple sclerosis. Eur Neurol. 1994;34:320–3.CrossRefGoogle Scholar
  22. 22.
    Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7.CrossRefGoogle Scholar
  23. 23.
    Tachibana N, Taniike M, Okinaga T, Ripley B, Mignot E, Nishino S. Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma. Sleep Med. 2005;6(6):567–9.CrossRefGoogle Scholar
  24. 24.
    Poirier G, Montplaisir J, Dumont M, Duquette P, Decary F, Pleines J, et al. Clinical and sleep laboratory study of narcoleptic symptoms in multiple sclerosis. Neurology. 1987;37(4):693–5.CrossRefGoogle Scholar
  25. 25.
    Omokawa M, Ayabe T, Nagai T, Imanishi A, Omokawa A, Nishino S, Sagawa Y, Shimizu T, Kanbayashi T. Am J, Med Genet A. Decline of CSF orexin (hypocretin) levels in Prader–Willi syndrome. 2016 May;170(5):1181–6.  https://doi.org/10.1002/ajmg.a.37542. (Epub 2016 Jan 6).CrossRefGoogle Scholar
  26. 26.
    Kanbayashi T, Imanishi A, Ohmori Y, Sagawa Y, Takahashi Y, Omokawa M, Sato M, Hishikawa Y, Shimizu T, Nishino S. Symptomatic narcolepsy or hypersomnolence with and without hypocretin (orexin) deficiency chap. 9. In: Goswami M, Thorpy MJ, Pandi-Perumal SR, editors. Narcolepsy a clinical guide, 2nd edn. Amsterdam: Springer International Publishing; 2016, pp. 95–128.CrossRefGoogle Scholar
  27. 27.
    Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2006;250(1–2):120–3.CrossRefGoogle Scholar
  28. 28.
    Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin Neurol Neurosurg. 2009;111(4):341–4.CrossRefGoogle Scholar
  29. 29.
    Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;57:2253–8.CrossRefGoogle Scholar
  30. 30.
    Overeem S, van Hilten J, Ripley B, Mignot E, Nishino S, Lammers G. Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology. 2002;58(3):498–9.CrossRefGoogle Scholar
  31. 31.
    Arii J, Kanbayashi T, Tanabe Y, Ono J, Nishino S, Kohno Y. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology. 2001;56(12):1775–6.CrossRefGoogle Scholar
  32. 32.
    Nokura K, Kanbayashi T, Ozeki T, Koga H, Senda M, Zettsu T, et al. Hypersomnia secondary to hypothalamic damage and CSF orexin-A level in four cases. Sleep. 2004;27(suppl):A249.Google Scholar
  33. 33.
    Sakuta K, Nakamura M, Komada Y, Yamada S, Kawana F, Kanbayashi T, et al. Possible mechanism of secondary narcolepsy with a long sleep time following surgery for craniopharyngioma. Intern Med. 2012;51(4):413–7.CrossRefGoogle Scholar
  34. 34.
    Uchida T, Kanbayashi T, Tanabe R, Nagasawa K, Ishii M. A case of a 13 year old girl who was diagnosed as narcolepsy with hypersomnia after surgery on craniopharyngioma. No To Hattatsu. 2014;46:423.Google Scholar
  35. 35.
    Arii J, Kanbayashi T, Miyamoto H, Suzuki H, Kondo H, Ishii M. A case with post-trumatic hypersomnia and low hypocretin/orexin level. JSSR abstract. 2004:257.Google Scholar
  36. 36.
    Tohyama J, Kanazawa O, Akasaka N, Kamimura T. A case of bilateral paramedian thalamic infarction in childhood with the sensory disturbance and the sensory loss of taste. No To Hattatsu. 2004;36(1):65–9.PubMedGoogle Scholar
  37. 37.
    Miyamoto T, Miyamoto M, Hirata K. Comparison of the three cases of nocturnal polysomnography in bilateral paramedian thalamic infarction. Jpn J Clin Neurophysiol. 2004;32(5):550.Google Scholar
  38. 38.
    Adachi T, Maeda H, Yoshimizu A, Iwata N, Yoshimura J, Sakai S, et al. A case with acute onset hypersomnolence. Mem Yamaguchi Med Soc. 2013;47:172.Google Scholar
  39. 39.
    Kashiwagi M, Tanabe T, Hara K, Suzuki S, Wakamiya E, Shimizu T, et al. Sleepiness due To Wernicke’s encephalopathy with bilateral hypothalamic lesion In A 5-year-old girl. Sleep. 2004;27:A315.Google Scholar
  40. 40.
    Yamato H, Tanozaki M, Seino Y, Wakasaya Y, Suda T, Baba M. A hypersomnia case due to limbic encephalitis with decreased orexin level. Rinsho Shinkeigaku Clin Neurol. 2004;44(7):482.Google Scholar
  41. 41.
    Sugeno N, Kawaguchi N, Hasegawa T, Kuroda T, Nakashima I, Kanbayashi T, et al. A case with anti-galactocerebroside antibody-positive Mycoplasma pneumoniae meningoencephalitis presenting secondary hypersomnia. Neurol Sci. 2012;33(6):1473–6.CrossRefGoogle Scholar
  42. 42.
    Mukaino A, Kinoshita I, Fukushima N, Otubo M, Kanbayashi T. A case of herpes simplex encephalitis with hypersomnia and low orexin level in the cerebrospinal fluid. Clin Neurol. 2014;54:207–11.Google Scholar
  43. 43.
    Maeda T, Nagata K, Kondo H, Kanbayashi T. Parkinson’s disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. Sleep Med. 2006;7(8):662.CrossRefGoogle Scholar
  44. 44.
    Wakai M, Kanbayashi T. Narcolepsy due to Parkinson’s disease with a decrease in cerebrospinal-fluid orexin: a case report. Sleep Biol Rhythms. 2011;9(2):2.CrossRefGoogle Scholar
  45. 45.
    Teraoka H, Yasui K, Nomura T, IIto S, Watanabe Y, Kowa H, et al. A case of Parkinson’s disease with hypersomnia and low CSF orexin level. Rinsho Shinkeigaku. 2013;53(5):389.Google Scholar
  46. 46.
    Hattori Y, Hattori T, Mukai E, Mori H, Mizuno Y, Kayukawa Y, et al. Excessive daytime sleepiness and low CSF orexin-A/hypocretin-I levels in a patient with probable progressive supranuclear palsy. No To Shinkei. 2003;55(12):1053–6.PubMedGoogle Scholar
  47. 47.
    Sugiura K, Kanbayashi T, Hattori N, Inoue Y. A case with narcolepsy which symptoms were exacerbated by comorbidity of progressive supranuclear palsy. Suimin Iryou. 2007;2(1):101–4.Google Scholar
  48. 48.
    Iseki K, Mezaki T, Oka Y, Terada K, Tomimoto H, Miki Y, et al. Hypersomnia in MS. Neurology. 2002;59(12):2006–7.CrossRefGoogle Scholar
  49. 49.
    Oka Y, Kanbayashi T, Mezaki T, Iseki K, Matsubayashi J, Murakami G, et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol. 2004;251(7):885–6.CrossRefGoogle Scholar
  50. 50.
    Kato T, Kanbayashi T, Yamamoto K, Nakano T, Shimizu T, Hashimoto T, et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med. 2003;42(8):743–5.CrossRefGoogle Scholar
  51. 51.
    Nozaki H, Katada S, Sato M, Tanaka K, Nishizawa M. A case with hypersomnia and paresthesia due to diffuse MS leisons from hypothalamus to spine. Rinsho Shinkeigaku Clin Neurol. 2004;44(1):59.Google Scholar
  52. 52.
    Nakamura M, Nishii M, Maki S, Nakamuara M, Suenaga T. A MS cses with EDS and bilateral hypothlamic lesions. Clin Neurol. 2005;45(2):187.Google Scholar
  53. 53.
    Baba T, Nakashima I, Kanbayashi T, Konno M, Takahashi T, Fujihara K, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol. 2009;256(2):287–8.CrossRefGoogle Scholar
  54. 54.
    Sekiguchi T, Ishibashi T, Kubodera T, Yokota T, Mizusawa H. A 41 year old female with anti-AQP4 related encephalitis had narcolepsy and autonomic disturbance at onset. Rinsho Shinkeigaku Clin Neurol. 2011;51(7):516.Google Scholar
  55. 55.
    Nakano T, Fujimoto T, Fukuda Y, Takahashi T, Kanbayashi T. Neuromyelitis optica with syndrome of inappropriate secretion of antidiuretic hormone and hypersomnia associated with bilateral hypothalamic lesions: a case report. Rinsho Shinkeigaku Clin Neurol. 2011;51(8):599–602.CrossRefGoogle Scholar
  56. 56.
    Deguchi K, Kono S, Deguchi S, Morimoto N, Ikeda M, Kurata T, et al. A patient with anti-aquaporin 4 antibody presenting hypersomnolence as the initial symptom and symmetrical hypothalamic lesions. J Neurol Sci. 2012;312(1–2):18–20.CrossRefGoogle Scholar
  57. 57.
    Suzuki K, Nakamura T, Hashimoto K, Miyamoto M, Komagamine T, Nagashima T, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch neurol. 2012;69(10):1355–9.CrossRefGoogle Scholar
  58. 58.
    Miyagawa S, Kitamura E, Uchino A, Kanbayashi T, Ogino M. A case of 27 year old woman who developed hypersomnia due to a large lesion of hypothalamus with anti-AQP4-antibody. Rinsho Shinkeigaku. 2013;53(2):169.Google Scholar
  59. 59.
    Sakai W, Matsui N, Fujita K, Izumi Y, Nishida Y, Takahashi T, et al. A case of neuromyelitis optica spectrum disorder associated with central pontine and extrapontine myelinolysis preceded by syndrome of inappropriate antidiuretic hormone secretion. Rinsho Shinkeigaku. 2014;54(7):556–60.CrossRefGoogle Scholar
  60. 60.
    Kume K, Deguchi K, Ikeda K, Takata T, Kokudo Y, Kamada M, et al. Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. Rinsho Shinkeigaku. 2014;54(4):364.Google Scholar
  61. 61.
    Saito N, Inoue M, Hasuo K, Kanbayashi T, Murayama S, Takeuchi S. A 39 years old woman responding to modafinil with bilateral hypothalamic lesion associated with hyperthermia and hypersomnia: a case report. Rinsho Shinkeigaku Clin Neurol. 2014;54(7):550–5.CrossRefGoogle Scholar
  62. 62.
    Kubota H, Kanbayashi T, Tanabe Y, Kohno Y. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol. 2002;17(7):537–9.CrossRefGoogle Scholar
  63. 63.
    Yoshikawa S, Suzuki S, Yamamoto K, Shichiri M, Miyamoto R, Kuroda K, et al. A case of acute disseminated encephalomyelitis associated with hypersomnia and low CSF hypocretin levels. Pediatric Neurol. 2004;31:367–70CrossRefGoogle Scholar
  64. 64.
    Yano T, Kanbayashi T, Sawaishi Y, Shimizu T, Takada G. An infant case of hypersomnia with acute disseminated encephalomyelitis due to hypothalamic dysfunction. Sleep. 2004;27(suppl):A238.Google Scholar
  65. 65.
    Mizuno K, Kiba Y, Yokoyama T, Tosho Y, Inoue M, Maeba H, et al. A case of ADEM with hypersomnolence associated with low CSF hypocretin-1 level. J Jpn Pediatr Soc. 2011;115(2):330.Google Scholar
  66. 66.
    Saji N, Kawarai T, Tadano M, Shimizu H, Kita Y, Susuki K, et al. Does CSF hypocretin-1 decrease in Bickerstaff’s brainstem encephalitis? Clin Neurol Neurosurg. 2007;109(6):547–8.CrossRefGoogle Scholar
  67. 67.
    Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, Watanabe M, et al. CSF hypocretin levels in Guillain-Barre syndrome and other infl amatory neuropathies. Neurology. 2003;61(6):823–5.CrossRefGoogle Scholar
  68. 68.
    Terashima H, Hoshino H, Ota S, Kashiwai H, Kubota M, Horikawa R, et al. A case of Prader-Willi Syndrome with temporary hypersomnic symptoms. No To Hattatsu. 2012;44(2):155.Google Scholar
  69. 69.
    Kanbayashi T, Abe M, Fujimoto S, Miyachi T, Takahashi T, Yano T, et al. Hypocretin deficiency in Niemann–Pick type C with cataplexy. Neuropediatrics. 2003;34(1):52–3.CrossRefGoogle Scholar
  70. 70.
    Oyama K, Takahashi T, Shoji Y, Oyamada M, Noguchi A, Tamura H, et al. Niemann–Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med. 2006;209(3):263–7.CrossRefGoogle Scholar
  71. 71.
    Soda M, Kanno K, Oguchi H, Matsumoto J, Itagaki S, Kobayashi N, et al. A case of Niemann–Pick disease type C with epilepsy, autistic symptoms, and narcolepsy associated with low CSF orexin level. Fukushima J Med Sci. 2011;61(3):184.Google Scholar
  72. 72.
    Eto K, Ito Y, Nishikawa A, Saito K, Kanbayashi T, Inoue T, et al. Use of clomipramine for cataplexy associated with Niemann–Pick disease type C. 2015 (Submitting).Google Scholar
  73. 73.
    Iwata T, Suzuki N, Mizuno H, Nakashima I, Kanbayashi T, Itoyama Y. A marked decrease of orexin in the cerebrospinal fluid in a patient with myotonic dystrophy type 1 showing an excessive daytime sleepiness. Rinsho Shinkeigaku. 2009;49(7):437–9.CrossRefGoogle Scholar
  74. 74.
    Omori Y, Kanbayashi T, Imanishi A, Tsutsui K, Sagawa Y, Kikuchi YS, Takeshima M, Yoshizawa K, Uemura S, Shimizu T. Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness. Neuropsychiatr Dis Treat. 2018;14:451–7.CrossRefGoogle Scholar
  75. 75.
    Sato T, Muroya K, Kanbayashi T. Components of excessive daytime sleepiness in patients with rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation. Pediatrics. http://pediatrics.aappublications.org/content/132/3/e788.long/reply-pediatrics_el_56631; 2014 (online).
  76. 76.
    Ito H, Ishimaru Y, Yatsuda K. A new onset and spontaneous remission case with Behcet’s disease during Infliximab treatment. Abstr Jpn Coll Rheumatol. 2007;51:412.Google Scholar
  77. 77.
    Lecendreux M, Maret S, Bassetti C, Mouren M, Tafti M. Clinical effi cacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12(4):347–8.CrossRefGoogle Scholar
  78. 78.
    Mignot E. Sleep, sleep disorders and hypocretin (orexin). Sleep Med. 2004;5(Suppl 1):2–8.CrossRefGoogle Scholar
  79. 79.
    Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991–7.CrossRefGoogle Scholar
  80. 80.
    Kanbayashi T, Ishiguro H, Aizawa R, Saito Y, Ogawa Y, Abe M, Hirota K, Nishino S, Shimizu T. Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barré syndrome. Psychiatry Clin Neurosci. 2002;56(3):273–4.CrossRefGoogle Scholar
  81. 81.
    Mishima K, Fujiki N, Yoshida Y, Sakurai T, Honda M, Mignot E, Nishino S. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep. 2008;31(8):1119–26.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Imanishi A, Kawazoe T, Hamada Y, Ohmori Y, Omokawa M, Sagawa Y, Takahashi Y, Takahashi J, Tsutsui K, Kanbayashi T, Sakai N, Shimizu T. Cerebrospinal fluid orexin levels in symptomatic narcolepsy-cataprexy, Niemann–pick type C. Abstract of 29st Annual Meeting of the Associated Professional Sleep Societies, A270. 2015.Google Scholar

Copyright information

© Japanese Society of Sleep Research 2018

Authors and Affiliations

  1. 1.Department of Systems Pharmacology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of NeuropsychiatryAkita University Graduate School of MedicineAkitaJapan
  3. 3.International Institute for Integrative Sleep Medicine (WPI-IIIS)University of TsukubaTsukubaJapan
  4. 4.Division of Allergy, Department of Medical SpecialtiesNational Center for Child Health and DevelopmentTokyoJapan
  5. 5.Sleep and Circadian Neurobiology LaboratoryStanford University School of MedicinePalo AltoUSA

Personalised recommendations